Copyright
©The Author(s) 2022.
World J Clin Cases. Feb 26, 2022; 10(6): 1852-1862
Published online Feb 26, 2022. doi: 10.12998/wjcc.v10.i6.1852
Published online Feb 26, 2022. doi: 10.12998/wjcc.v10.i6.1852
Ref. | Yr | Study location | Surgery type | Sample size | Age (yr) | Common protocol for PVB | Opioid added to PVB in intervention group) | Drug added to PVB in control group | Post-operative analgesics used | |
Study | Control | |||||||||
Mostafa et al[21] | 2018 | Egypt | MRM or breast conservation surgery with axillary node dissection | 20 | 20 | 18-78 | Nalbuphine 10 mg | PVB at the level of T4 with bupivacaine 0.5% 0.3 mL/kg | No drug | Tramadol as PCA |
Pushparajan et al[22] | 2017 | India | MRM | 20 | 20 | 18-60 | Fentanyl 2 μg/mL at 0.1 mL/kg/h for 24 h | Continuous PVB at the level of T4 with 0.2% ropivacaine for 24 h | No drug | Fentanyl as PCA. Paracetamol or tramadol or fentanyl for breakthrough pain |
Morsy et al[23] | 2017 | Egypt | MRM | 15 | 15 | NR | Morphine 2 mg | PVB at the level of T3 with 20 mL of bupivacaine 0.25% | No drug | Meperidine for breakthrough pain |
Bhuvaneshwari et al[24] | 2012 | India | Total mastectomy and axillary lymph node dissection | 12 | 12 | Study: 49.1 ± 7.1; Control: 50.7 ± 11 | Fentanyl 2 μg/mL | PVB at the level of T3 with bupivacaine 0.25% and epinephrine 5 μg/mL | No drug | Morphine for breakthrough pain |
Omar et al[25] | 2011 | Egypt | MRM | 19 | 20 | Study: 47.5 ± 9.3; Control: 49.3 ± 10.5 | Tramadol 1.5 mg/kg (maximum of 150 mg) | PVB at the level of T1 (1/3rd of the dose) and T4 (2/3rd of the dose) with bupivacaine 0.5% 2 mg/kg | No drug | Fentanyl as PCA. Paracetamol 1 g thrice daily and ibuprofen 400-600 mg thrice daily |
Burlacu et al[26] | 2006 | Ireland | Wide local excisions (at least one breast quadrant), mastectomies, and mastectomies with reconstruction | 13 | 13 | Study: 54 ± NR; Control: 51 ± NR | Fentanyl 50 μg with bolus followed by 4 μg/mL infusion | Continuous PVB at the level of T3 with initial bolus of 19 mL levobupivacaine 0.25% followed by continuous infusion of 0.1% solution for 24 h | Saline | Morphine as PCA |
Ref. | Outcome | Results |
Mostafa et al[21] | Time to first analgesic request | Significantly longer in the opioid group |
Post-operative analgesic time | Significantly longer in the opioid group | |
24 h total analgesic consumption | Significantly lower in the opioid group | |
Pain scores up to 24 h | Significantly lower in the opioid group | |
HR, SBP, DBP | No difference between the two groups | |
Ramsay sedation scores | Patients in the control group were more agitated then opioid group in the first four hours after the operation. No difference between the two groups after four hours | |
Pushparajan et al[22] | Pain scores up to discharge | Significantly lower scores in the opioid group only at 24 h and not at other time periods |
24 h total analgesic consumption | No difference between the two groups | |
PONV | No difference between the two groups | |
Urinary retention, pruritis | No difference between the two groups | |
Patient satisfaction | No difference between the two groups | |
Morsy et al[23] | 24 h total analgesic consumption | No difference between the two groups |
Time to first analgesic request | No difference between the two groups | |
Ramsay sedation scores | No difference between the two groups | |
PONV | No difference between the two groups | |
HR, SBP, DBP | No difference between the two groups | |
Bhuvaneshwari et al[24] | Time to first analgesic request | Significantly longer in the opioid group |
24 h total analgesic consumption | Significantly lower in the opioid group | |
Cumulative pain scores at 24 h | Significantly lower in the opioid group | |
PONV | No difference between the two groups | |
Patient satisfaction | Significantly higher in the opioid group | |
Omar et al[25] | Time to first analgesic request | No difference between the two groups |
24 h total analgesic consumption | No difference between the two groups | |
Pain scores up to 24 h | No difference between the two groups | |
PONV | No difference between the two groups | |
Burlacu et al[26] | Total analgesic consumption | Significantly lower in the opioid group |
Pain scores up to 24 h | No difference between the two groups | |
Nausea scores | Significantly higher in the opioid group | |
SBP | No difference between the two groups | |
Patient satisfaction | Significantly higher in the opioid group |
Ref. | Random sequence generation | Allocation concealment | Blinding of participants and personnel | Blinding of outcome assessment | Incomplete outcome data | Selective reporting | Other bias |
Mostafa et al[21] | Low risk | Low risk | Low risk | Low risk | Low risk | High risk | Low risk |
Pushparajan et al[22] | Low risk | Unclear risk | Low risk | Low risk | Low risk | Low risk | Low risk |
Morsy et al[23] | Unclear risk | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk | Low risk |
Bhuvaneshwari et al[24] | Low risk | Unclear risk | Low risk | Low risk | Low risk | Low risk | Low risk |
Omar et al[25] | Low risk | Unclear risk | Low risk | Low risk | Low risk | Low risk | Low risk |
Burlacu et al[26] | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk |
- Citation: Chen MH, Chen Z, Zhao D. Impact of adding opioids to paravertebral blocks in breast cancer surgery patients: A systematic review and meta-analysis. World J Clin Cases 2022; 10(6): 1852-1862
- URL: https://www.wjgnet.com/2307-8960/full/v10/i6/1852.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i6.1852